G-protein coupled receptor kinase-5 polymorphism
AssigneeUniversity of Cincinnati
InventorsGerald W. Dorn, Stephen B. Liggett
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods relating to a G-protein coupled receptor kinase-5 polymorphism. The methods include, for example: detecting enhanced desensitization of the beta adrenergic receptor signaling pathway in an individual, assessing partial protection against heart failure progression in an individual, and assessing an individual's response to beta-blocker therapy. The compositions include polynucleotides or fragments thereof of a nucleotide sequence encoding for a G-protein receptor kinase-5 molecule with a thymine at amino acid position 122 and oligonucleotide primers that hybridize thereto.
Claims22
A method for detecting enhanced desensitization of the beta adrenergic receptor signaling pathway in an individual, comprising:
- a) obtaining a sample comprising a polynucleotide encoding a G-protein coupled receptor kinase 5 molecule or a fragment of the polynucleotide from the individual, and
- b) determining if the polynucleotide or fragment contains a polymorphic site which results in a leucine at amino acid position 41, wherein the presence of leucine at the polymorphic site indicates an enhanced desensitization of the beta adrenergic receptor signaling pathway.
A method for assessing partial protection against heart failure progression in an individual, comprising:
- a) obtaining a sample comprising a polynucleotide encoding a G-protein coupled receptor kinase 5 molecule or a fragment of the polynucleotide from the individual, and
- b) determining if the polynucleotide or fragment contains a polymorphic site which results in a leucine at amino acid position 41, wherein the presence of leucine at the polymorphic site indicates partial protection against heart failure progression in the individual.
A method of assessing an individual's response to beta-blocker therapy, comprising:
- a) obtaining a sample comprising a polynucleotide encoding a G-protein coupled receptor kinase 5 molecule or a fragment of the polynucleotide from the individual, and
- b) determining if the polynucleotide or fragment contains a polymorphic site which results in a leucine at amino acid position 41, wherein the presence of leucine at the polymorphic site indicates a reduced responsiveness to beta-blocker therapy.
A polynucleotide or fragment thereof of a nucleotide sequence encoding a G-protein coupled receptor kinase 5 molecule comprising a thymine at nucleotide position 122.
An oligonucleotide primer that hybridizes to a polynucleotide encoding a G-protein coupled receptor kinase 5 or a fragment of the polynucleotide, wherein the polynucleotide or fragment comprise a thymine at nucleotide position 122.
Dependencies are inferred from the claim text.